New Risk • May 07
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 6.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Mar 30
Suzhou Zelgen Biopharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Reported Earnings • Mar 02
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: CN¥0.61 loss per share (further deteriorated from CN¥0.52 loss in FY 2024). Revenue: CN¥812.7m (up 53% from FY 2024). Net loss: CN¥160.7m (loss widened 17% from FY 2024). Revenue missed analyst estimates by 3.7%. Earnings per share (EPS) also missed analyst estimates by 83%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Dec 26
Suzhou Zelgen Biopharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Mar 28, 2026 Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Mar 28, 2026 New Risk • Oct 31
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 10.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 31
Third quarter 2025 earnings released: CN¥0.073 loss per share (vs CN¥0.12 loss in 3Q 2024) Third quarter 2025 results: CN¥0.073 loss per share (improved from CN¥0.12 loss in 3Q 2024). Revenue: CN¥217.8m (up 52% from 3Q 2024). Net loss: CN¥20.6m (loss narrowed 34% from 3Q 2024). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Suzhou Zelgen Biopharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Reported Earnings • Aug 24
Second quarter 2025 earnings released Second quarter 2025 results: Revenue: CN¥208.0m (up 57% from 2Q 2024). Net loss: CN¥44.5m (loss widened 65% from 2Q 2024). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in China. Announcement • Jun 30
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Suzhou Zelgen Biopharmaceuticals Co.,Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 New Risk • May 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Breakeven Date Change • Apr 24
Forecast breakeven date pushed back to 2026 The 4 analysts covering Suzhou Zelgen BiopharmaceuticalsLtd previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 77% to 2025. The company is expected to make a profit of CN¥310.0m in 2026. Average annual earnings growth of 99% is required to achieve expected profit on schedule. Reported Earnings • Apr 23
First quarter 2025 earnings released: CN¥0.11 loss per share (vs CN¥0.15 loss in 1Q 2024) First quarter 2025 results: CN¥0.11 loss per share (improved from CN¥0.15 loss in 1Q 2024). Revenue: CN¥167.6m (up 55% from 1Q 2024). Net loss: CN¥28.3m (loss narrowed 28% from 1Q 2024). Revenue is forecast to grow 62% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 20
Suzhou Zelgen Biopharmaceuticals Co.,Ltd., Annual General Meeting, May 16, 2025 Suzhou Zelgen Biopharmaceuticals Co.,Ltd., Annual General Meeting, May 16, 2025, at 13:30 China Standard Time. Location: 7F, No. 1277, Qianjin West Road, Kunshan, Jiangsu China Announcement • Mar 28
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. to Report Q1, 2025 Results on Apr 19, 2025 Suzhou Zelgen Biopharmaceuticals Co.,Ltd. announced that they will report Q1, 2025 results on Apr 19, 2025 Reported Earnings • Feb 27
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: CN¥0.51 loss per share (improved from CN¥1.09 loss in FY 2023). Revenue: CN¥533.9m (up 38% from FY 2023). Net loss: CN¥136.2m (loss narrowed 51% from FY 2023). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 26%. Revenue is forecast to grow 58% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth. Announcement • Dec 27
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2025 Suzhou Zelgen Biopharmaceuticals Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 19, 2025 Price Target Changed • Nov 01
Price target increased by 18% to CN¥79.00 Up from CN¥67.00, the current price target is provided by 1 analyst. New target price is 26% above last closing price of CN¥62.94. Stock is up 40% over the past year. The company is forecast to post a net loss per share of CN¥0.71 next year compared to a net loss per share of CN¥1.09 last year. Reported Earnings • Oct 26
Third quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.34 loss in 3Q 2023) Third quarter 2024 results: CN¥0.12 loss per share (improved from CN¥0.34 loss in 3Q 2023). Revenue: CN¥143.4m (up 131% from 3Q 2023). Net loss: CN¥31.4m (loss narrowed 64% from 3Q 2023). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Suzhou Zelgen Biopharmaceuticals Co.,Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Major Estimate Revision • Sep 11
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥699.3m to CN¥623.6m. Forecast losses increased from -CN¥0.63 to -CN¥0.777 per share. Biotechs industry in China expected to see average net income growth of 32% next year. Consensus price target up from CN¥64.00 to CN¥67.00. Share price rose 7.4% to CN¥61.48 over the past week. Reported Earnings • Aug 24
Second quarter 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.22 loss in 2Q 2023) Second quarter 2024 results: CN¥0.10 loss per share (improved from CN¥0.22 loss in 2Q 2023). Revenue: CN¥132.5m (up 19% from 2Q 2023). Net loss: CN¥27.0m (loss narrowed 53% from 2Q 2023). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. to Report First Half, 2024 Results on Aug 24, 2024 Suzhou Zelgen Biopharmaceuticals Co.,Ltd. announced that they will report first half, 2024 results on Aug 24, 2024 Announcement • Jun 08
Suzhou Zelgen Biopharmaceuticals Co.,Ltd., Annual General Meeting, Jun 28, 2024 Suzhou Zelgen Biopharmaceuticals Co.,Ltd., Annual General Meeting, Jun 28, 2024, at 13:30 China Standard Time. Location: 4F, No. 258, Dengyun Road, Yushan Town, Kunshan, Jiangsu China Major Estimate Revision • May 08
Consensus revenue estimates decrease by 15% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from CN¥957.2m to CN¥816.2m. EPS estimate reaffirmed at -CN¥0.26 per share. Biotechs industry in China expected to see average net income growth of 36% next year. Consensus price target of CN¥64.00 unchanged from last update. Share price was steady at CN¥55.29 over the past week. Major Estimate Revision • May 02
Consensus EPS estimates upgraded to CN¥0.26 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from CN¥1.02b to CN¥957.2m. 2024 losses expected to reduce from -CN¥0.527 to -CN¥0.26 per share. Biotechs industry in China expected to see average net income growth of 35% next year. Consensus price target up from CN¥58.00 to CN¥64.00. Share price rose 7.7% to CN¥55.10 over the past week. Reported Earnings • Apr 20
First quarter 2024 earnings released: CN¥0.15 loss per share (vs CN¥0.24 loss in 1Q 2023) First quarter 2024 results: CN¥0.15 loss per share (improved from CN¥0.24 loss in 1Q 2023). Revenue: CN¥108.2m (flat on 1Q 2023). Net loss: CN¥39.5m (loss narrowed 31% from 1Q 2023). Revenue is forecast to grow 75% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Mar 30
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. to Report Q1, 2024 Results on Apr 20, 2024 Suzhou Zelgen Biopharmaceuticals Co.,Ltd. announced that they will report Q1, 2024 results on Apr 20, 2024 Reported Earnings • Feb 24
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: CN¥1.09 loss per share (improved from CN¥1.91 loss in FY 2022). Revenue: CN¥386.4m (up 28% from FY 2022). Net loss: CN¥279.0m (loss narrowed 39% from FY 2022). Revenue missed analyst estimates by 9.9%. Earnings per share (EPS) exceeded analyst estimates by 7.2%. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.49 loss in 3Q 2022) Third quarter 2023 results: CN¥0.34 loss per share (improved from CN¥0.49 loss in 3Q 2022). Revenue: CN¥62.2m (down 33% from 3Q 2022). Net loss: CN¥87.9m (loss narrowed 25% from 3Q 2022). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 26
Second quarter 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.53 loss in 2Q 2022) Second quarter 2023 results: CN¥0.22 loss per share (improved from CN¥0.53 loss in 2Q 2022). Revenue: CN¥111.8m (up 81% from 2Q 2022). Net loss: CN¥57.0m (loss narrowed 55% from 2Q 2022). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). Deputy General Manager & Director Binhua Lv was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 24
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: CN¥1.73 loss per share (down from CN¥1.36 loss in FY 2020). Revenue: CN¥201.1m (up CN¥173.4m from FY 2020). Net loss: CN¥414.5m (loss widened 30% from FY 2020). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) exceeded analyst estimates by 4.8%. Over the next year, revenue is forecast to grow 213%, compared to a 40% growth forecast for the pharmaceuticals industry in China. Breakeven Date Change • Sep 14
Forecast to breakeven in 2022 The analyst covering Suzhou Zelgen Biopharmaceuticals expects the company to break even for the first time. New forecast suggests the company will make a profit of CN¥313.0m in 2022. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Breakeven Date Change • Sep 13
Forecast to breakeven in 2022 The analyst covering Suzhou Zelgen Biopharmaceuticals expects the company to break even for the first time. New forecast suggests the company will make a profit of CN¥313.0m in 2022. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Breakeven Date Change • Sep 10
Forecast to breakeven in 2022 The analyst covering Suzhou Zelgen Biopharmaceuticals expects the company to break even for the first time. New forecast suggests the company will make a profit of CN¥313.0m in 2022. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Breakeven Date Change • Sep 07
Forecast to breakeven in 2022 The analyst covering Suzhou Zelgen Biopharmaceuticals expects the company to break even for the first time. New forecast suggests the company will make a profit of CN¥313.0m in 2022. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Breakeven Date Change • Sep 06
Forecast to breakeven in 2022 The analyst covering Suzhou Zelgen Biopharmaceuticals expects the company to break even for the first time. New forecast suggests the company will make a profit of CN¥313.0m in 2022. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Breakeven Date Change • Sep 02
Forecast to breakeven in 2022 The analyst covering Suzhou Zelgen Biopharmaceuticals expects the company to break even for the first time. New forecast suggests the company will make a profit of CN¥313.0m in 2022. Average annual earnings growth of 60% is required to achieve expected profit on schedule. Price Target Changed • Jun 09
Price target decreased to CN¥105 Down from CN¥128, the current price target is provided by 1 analyst. New target price is 40% above last closing price of CN¥74.86. Stock is down 3.3% over the past year. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥56.95 The company is down 44% from its price of CN¥101 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period. Is New 90 Day High Low • Dec 09
New 90-day low: CN¥70.35 The company is down 3.0% from its price of CN¥72.82 on 10 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. Announcement • Oct 29
Suzhou Zelgen Biopharmaceuticals Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020 Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that they will report Q3, 2020 results on Oct 30, 2020 Announcement • Jul 06
Suzhou Zelgen Biopharmaceuticals Co., Ltd. to Report Q2, 2020 Results on Aug 17, 2020 Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that they will report Q2, 2020 results on Aug 17, 2020 
